{"title":"Disease management of malignant struma ovarii.","authors":"Yanli Ning, Cen Lou, Zhongke Huang","doi":"10.1967/s002449912760","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Ovarian goiter that meets the diagnostic criteria for malignant thyroid tumors or has invasive distant metastasis is called malignant struma ovarii (MSO). The incidence of MSO is very low. The level of serum thyroglobulin (Tg) is helpful to differentiate MSO with highly differentiated pathological type from other ovarian malignancies. But its therapeutic method is currently debated. Herein, we present a case of 54 years old woman, who was admitted to hospital due to frequent abdominal pain for 9 months and with normal serum Tg. Postoperative pathological examination revealed highly differentiated follicular thyroid carcinoma of bilateral ovarian origin, which penetrated bilateral ovarian cortex, involved the serosal surface of left fallopian tube and disseminated to sigmoid mesentery, small intestinal mesentery and pelvic cavity. The disseminated lesions were considered to originate from right ovary. After the total thyroidectomy, iodine-131(<sup>131</sup>I) treatment was performed with a dose of 150mCi. The <sup>131</sup>I whole-body scintigraphy (WBS) 2 days after treatment showed residual thyroid tissue in the neck and implantation metastasis in mesentery. After 1-year regular follow-up, no significant abnormalities were found in tumor indicators, Tg, thyroid function, neck ultrasound and abdominopelvic enhanced computed tomography (CT). This MSO case with normal Tg and multiple implantation metastasis aimed to discuss its clinical management especially for Tg and <sup>131</sup>I and to improve its prognosis.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"247-250"},"PeriodicalIF":0.9000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hellenic journal of nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1967/s002449912760","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/9 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Ovarian goiter that meets the diagnostic criteria for malignant thyroid tumors or has invasive distant metastasis is called malignant struma ovarii (MSO). The incidence of MSO is very low. The level of serum thyroglobulin (Tg) is helpful to differentiate MSO with highly differentiated pathological type from other ovarian malignancies. But its therapeutic method is currently debated. Herein, we present a case of 54 years old woman, who was admitted to hospital due to frequent abdominal pain for 9 months and with normal serum Tg. Postoperative pathological examination revealed highly differentiated follicular thyroid carcinoma of bilateral ovarian origin, which penetrated bilateral ovarian cortex, involved the serosal surface of left fallopian tube and disseminated to sigmoid mesentery, small intestinal mesentery and pelvic cavity. The disseminated lesions were considered to originate from right ovary. After the total thyroidectomy, iodine-131(131I) treatment was performed with a dose of 150mCi. The 131I whole-body scintigraphy (WBS) 2 days after treatment showed residual thyroid tissue in the neck and implantation metastasis in mesentery. After 1-year regular follow-up, no significant abnormalities were found in tumor indicators, Tg, thyroid function, neck ultrasound and abdominopelvic enhanced computed tomography (CT). This MSO case with normal Tg and multiple implantation metastasis aimed to discuss its clinical management especially for Tg and 131I and to improve its prognosis.
期刊介绍:
The Hellenic Journal of Nuclear Medicine published by the Hellenic Society of
Nuclear Medicine in Thessaloniki, aims to contribute to research, to education and
cover the scientific and professional interests of physicians, in the field of nuclear
medicine and in medicine in general. The journal may publish papers of nuclear
medicine and also papers that refer to related subjects as dosimetry, computer science,
targeting of gene expression, radioimmunoassay, radiation protection, biology, cell
trafficking, related historical brief reviews and other related subjects. Original papers
are preferred. The journal may after special agreement publish supplements covering
important subjects, dully reviewed and subscripted separately.